Site Admin 24/02/2026 Site Admin 24/02/2026

Why Clinical Trials Need Decision Intelligence

Over the past three decades in clinical research, development outsourcing, and patient access, I have watched trial execution steadily improve. Systems are more sophisticated. Automation is more prevalent. Operational discipline is stronger.

Yet we still do not reliably understand, capture, or reuse how the best decisions are made. Decision-making quality, consistency, and traceability have not advanced at the same pace

Today’s clinical infrastructure benefits from robust systems—such as Clinical Trial Management Systems (CTMS), Enterprise Resource Planning (ERP), Quality Management Systems (QMS), financial tools, and contract lifecycle management. But, the economic and governance decisions that shape these systems remain fragmented, siloed, and overly reliant on intuition rather than structured logic.

The consequences are familiar

Incentives misaligned between sponsors, CROs, and sites.
Budget challenges arise late in the process.
Amendments can undermine leadership confidence.
Outcomes of negotiation and collaboration vary widely across programs.
Participant burdens often manifest only after retention issues become apparent.

These challenges are not operational hurdles; they stem from gaps in decision-making structures.

A Case in Point

Consider a practical example from an oncology program in which the reimbursable Target Product Profile (rTPP) evolved during development. While payer positioning broadened, the expectations for evidence grew more stringent. Although the scientific logic was sound, a structured approach to economic realignment was missing.

This oversight led to a cascade of reactive actions:

Trial complexity increased to support payer-relevant endpoints
Sample size and cost assumptions shifted late
CRO and vendors scope and responsibilities expanded without recalibrated performance incentives
Clinical Operations, Finance, and Outsourcing teams operated under different assumptions.
Market access strategies difrated from development cost assumptions.

Individually, each decision made sense; however, collectively, they introduced variability, quality, data compliance risks, and uncertainty regarding capital.

A Decision Intelligence Layer

What is needed is a Clinical Trial Decision Intelligence layer. A structured layer that strengthens how economic design, negotiation logic, and governance alignment are shaped — before execution systems take over

At RHIEOS, we focus on three pillars:

Enhance Economic Design

When the rTPP shifts, economic implications are modelled structurally—budget prescriptions, incentive alignment, payment logic, and participant burdens—before negotiations start.

Improve Negotiation Intelligence

Concession pathways and potential economic implications are illuminated upfront, reducing defensive posture and lowring amendment risk.

Establish Governance Coherence

Structured decision logic is captured and made reusable across studies and programs, aligning Clinical, Finance, Outsourcing, and Leadership around shared reasoning

Over time, these decisions can transform into program-level intelligence rather than remaining isolated transactions.

Why This Matters Now While AI systems will continue to expedite operations, poorly structured decisions made faster can inherently increase risk. The next phase of clinical infrastructure must prioritize not only efficiency but also effective coherence.

Decision coherence reduces variability, aligns incentives, lowers amendment risk, and strengthens capital confidence It is about strengthening how trials are economically designed, negotiated, and governed.

Begin with One Study:

Improve budget confidence.
Enhance negotiation consistency.
Align incentives from the outset.
Make participant burdens transparent during the design phase.

If decision-making becomes structured and reusable, value compounds across programs. In my experience, this approach leads to improved outcomes for all stakeholders—not just improved processes.

Site Admin 19/01/2026 Site Admin 19/01/2026

Part 2 - Zero-Redline Thinking: How to Build Resilient Contracts That Win Clinical Trials

The Contracts Manager rose to circulate what looked like one-page flyers he had been guarding closely throughout the meeting. Legal counsel gave him a quizzical look.

He explained that the document was a short-form Clinical Trial Agreement (CTA)—written in plain language, distilled from the company’s standard template and previously executed contracts.

“Is it understandable, flexible, balanced, and usable?” he asked. “Does it cover the essentials—scope, risk, payment, and data rights?”

Legal responded first: the form didn’t comply with company policy, and most sites would never agree to it.

The manager smiled.

“That’s exactly the point,” he said. “If contracts were designed this way—so clear and balanced that no one felt compelled to redline them—we’d eliminate months of negotiation. A CTA now takes three to four months to finalize; an amendment can take an additional one to two months.”

He paused.

“We’re dissatisfied with the quality of our agreements and collaborations—across CROs, labs, technical services, and partnerships. These failures compound.

“Imagine if a design-for-trust template, backed by coherent policies, guidelines, and playbooks, could remove all that pain.”

Silence settled in the room.

Eleanor sensed that the Zero-Redline idea had landed. It was, in essence, a proposal to redesign the contract itself—not as a legal weapon, but as a tool for trust and collaboration.

Why Contracts Fail

Weeks passed after the pre-mortem, and turning insight into an agreed plan proved harder than expected. Approval across departments stalled. The issue eventually reached the executive level, since it implied revisiting corporate policy.

The Contracts Manager’s radical one-page CTA was set aside, but his questions had opened a door.

Teams combed through legacy and active contracts, analyzing negotiation logs and outcomes to trace the roots of failure.

Painful stories surfaced.

In one study, site activation was delayed for weeks—patients waited—because parties couldn’t agree on the indemnification cap. In another, disputes erupted over whether the budget covered unscheduled patient visits.

Patterns emerged.

Key contributors included:

Disconnect between policy and practice: gaps between stated values and operational reality embedded in SOPs, playbooks, and templates.
Misaligned priorities: sponsors, sites, and CROs entering negotiations with divergent incentives and expectations
Imbalanced standard terms: boilerplate clauses perceived as one-sided, prolonging negotiation cycles.
Lack of clarity in key elements: objectives, scope, logistics, and payment terms left vague or inconsistently applied.
Inefficient review cycles: repeated drafting rounds eroding trust, momentum, and morale.
Non-standard handling of sensitive clauses: intellectual property, data ownership, publication rights, and indemnification diverging from accepted norms.
Overly rigid templates and legalistic language: dense structures discouraging comprehension and systemic problem-solving.
Poorly aligned incentives: contractual goals failing to reinforce collaboration or shared success.

The conclusion was uncomfortable but unmistakable: the system itself was failing.

Turning Foresight into Action

The pre-mortem revealed that most breakdowns clustered into three systemic categories:

Governance — policies and contractual frameworks
Guidelines and Tools — playbooks, negotiation processes, review practices
Goals and Roles — clarity of objectives, accountability, and performance measures

Contracting could not be fixed in fragments. It required integrated redesign—a cultural and procedural recalibration.

They began with governance. Policies were aligned with ISO 9001 (quality management) and ISO 44001 (collaborative business relationships), establishing a shared language for consistency, transparency, and trust.

Next came tools.

Templates and playbooks were rewritten with a single mandate: make them usable.

The goal was not to simplify the law, but to make legal structure intelligible to those executing it. Each clause carried plain-language guidance explaining intent and risk.

A Contract Review Checklist helped identify red flags early. But to create visibility across studies, they formalized this knowledge into a Clinical Trial Agreement Inventory and assessment tool (CTAide, its digital companion)

Clinical Trial Agreement Inventory provided a structured reference for developing or reviewing CTAs. It maps essential elements—scope, risk, governance, payment, data—and highlights common negotiation pitfalls. It helps reviewers see what is covered, what is missing, and what requires escalation**.

CTAide analyzes agreements for completeness, balance, and usability—flagging clauses that are one-sided or ambiguous. It quantifies risk exposure and visualizes balance across sponsor, CRO, and institution.

Together, these tools turned the Zero-Redline aspiration into something tangible: a trust instrument that could evolve with each negotiation.

In effect, CTAide became a translation layer between human intention and institutional memory—encoding fairness, balance, and precedent into the contracting system itself.

Finally, the focus turned to people.

Policies and tools were necessary, but capability was the multiplier.

Eleanor championed cross-functional training sessions simulating negotiations under real time pressure. The exercises built fluency, empathy, and systems thinking—qualities no software could automate.

“We’re not just contracting faster,” she told the team. “We’re contracting smarter.”

Contracts as the Capstone of Collaboration

Weeks later, Eleanor paused by the watercooler before another program meeting.

A milestone echoed in her mind: forty-five days to site activation; contracts signed on the final day.

The weight was real—and not hers alone.

Even with everything in place, trials could falter.

Yet every failure left traces: a shard of insight into disease progression, a clue to biology’s hidden logic, a refinement of what would not work.

Each study contributed a piece to the Alzheimer’s puzzle.

The contract, she realized, was more than a legal checkpoint. It was both signal and artifact—evidence that trust had been forged and alignment reached.

Like a capstone set atop an arch, it completed a structure that, though fragile, pointed forward.

Beneath that arch lay not just the promise of one therapy, but the shared pursuit of cures yet to come.

She took her glass of water, smiled at the doodle in her notebook—a timeline knocked over by a redline—and felt, for once, that the team had built something resilient enough not merely to endure reality, but to shape it—to give their science its best chance to succeed.

Acknowledgment

CTAide ™ was developed by RHIEOS Ventures in collaboration with Engage Clinical Contract Solutions.

Clinical Trial Agreement Inventory ™ is developed and owned by Engage Clinical Contract Solutions.

Part 1- Why Trials Falter Before They Begin

Eleanor is energized after her second cup of ristretto. It’s a few minutes before her eight o’clock clinical program-planning meeting — the one that could shape her company’s future and the prospects for patients with Alzheimer’s disease.

As program lead at AlphaBeta Inc., a mid-sized biotech advancing a novel cell therapy for neurological disorders, her team is responsible for both clinical studies and regulatory approval. She’s a drug-development scientist with deep field experience and has seen firsthand the devastating effects of Alzheimer’s and dementia on patients and their families.

A global network of collaborators — medical, clinical operations, finance, legal, hospitals, service providers, patient groups, and more — each holds a stake and a say in the discovery voyage. It’s a daunting challenge — like steering a kayak crew through turbulent waters.

Eleanor’s task seems deceptively simple: design a plan robust enough to meet the board’s ambitious target — three clinical studies in four years.
“It’s a feasible undertaking,” the Chief Medical Officer had said when she asked how the numbers were set.
She nodded, though her stomach tightened. She had seen aspirational targets like this before; they often place crushing pressure on teams and invite mistakes. The ristretto steadied her nerves as she walked to the meeting room.

Study Pre-mortem

Instead of rehearsing hopeful projections, Eleanor’s team turns to a pre-mortem — an exercise in imagining failure before it happens. The idea, developed by cognitive psychologist Gary Klein in 2007, is simple: assume the trial has already failed, then work backward to uncover why.

The method punctures comforting myths. It reveals that what most often delays trial start-ups isn’t contracts or budgets but the overlooked fundamentals — weak protocol design, poor feasibility, hasty site selection, and relationships that were never cultivated.

A Back-to-the-Future View

As Eleanor entered the meeting room, she noticed the Chief Medic and leaders from finance, legal, and HR clustered on one side of the U-shaped table. Opposite them sat the heads of clinical and functional groups — fault lines already visible. Quality and medical experts took up the flanks, ready to tend to any “casualties.”

The mood lightened when Eleanor invited everyone to share a witty line about why the program might fail.
“Every study team has a neat timeline until the redlined CTA punches it in the face,” the Contracts Manager quipped.
“Ouch — I didn’t see that coming,” she said, smiling as the room laughed.

The exercise produced over 130 one-liners, later distilled into a few central themes.

It all begins with the target product profile — the document defining the desired characteristics and therapeutic purpose of the investigational drug. When that profile is incomplete or unrealistic, it ripples through to poor protocol design and limited feasibility, making it hard to recruit eligible patients or sites.

That, in turn, leads to a strenuous path through country-specific regulatory hurdles. Misalignment of goals, priorities, and capabilities among all parties quickly follows. Add in multiple systems and administrative layers, and the mix breeds delays, stress, and preventable mistakes.

Hindsight and Reality Checks

The head of Quality, quiet until now, stood and wrote two words on the flip chart: complex system. He explained that clinical trials, like startups, behave as complex adaptive systems — dynamic, nonlinear, and full of surprises. The room fell silent. Good sign, thought Eleanor.

He launched into a crisp, ten-minute TED-style talk. Silence lingered afterward. Eleanor sensed the CMO wasn’t fully persuaded but had no alternative hypothesis to offer.

“Imagine a loose flotilla of kayakers from different tribes trying to navigate rapids without a skipper,” the Quality head said. “A small shift can upend the entire group — or the entire trial.”
“No wonder more than 90% of studies fail,” someone murmured.

The group moved on to discuss how to avoid those failures.

“We need clear goals with partners — and commitment tied to the right incentives,” said the Chief Medic.
“We must stay adaptable and open in how we work,” added the ClinOps head, smiling wryly.
“Contracts should be tools for trust — where minds, intent, and understanding meet,” said another. “Friction in contracts is often an early warning sign of deeper issues.”
The HR lead added, “We should be as competent in collaboration as we are in negotiation.”
Eleanor concluded: “We learn fast, surface risks early, and dedicate resources to fix them.”
Around the room, heads nodded.

Contracts: Trust Handrails not straitjackets

Contracts are the final step before a trial can begin. Yet long before formal negotiation starts, deal-making is already underway — budget discussions, staffing debates, early talks with investigators, and informal understandings with regulators, sites, and CROs.

Even when nothing is yet signed, expectations may have been set. So the later back-and-forth between legal teams and the drawn-out budget haggling should surprise no one; they often reveal gaps in trust and understanding. When sponsors, sites, and CROs can’t find common ground, the discord tends to echo through every subsequent stage of the study.

Precise language on standard provisions is necessary, but collaboration thrives in the spaces between the words and numbers — in shared intent, transparency, and goodwill.

And even when trust flows freely and contracts function smoothly, studies can still fail: too few patients enroll; endpoints fall short; safety concerns outweigh benefits; or biology simply refuses to cooperate. Eleanor knew all this.

But as the team sat around the U-shaped table, sketching out what might go wrong, she felt a cautious hope. They were, at last, beginning to name the real risks.

In the next part, we’ll follow their journey to design a system built to survive that uncertainty — the Zero-Redline approach.

Site Admin 28/04/2025 Site Admin 28/04/2025

Discovering the Hidden Questions: Toward Solving the Problems We Don’t Yet See

“our “simple task” as a research-to-care enterprise is to ensure that we keep to our ethical foundational principles constant”

— Participant